CAMBRIDGE, Mass., Aug. 1, 2018 /PRNewswire/ -- Blueprint Medicines
Corporation (NASDAQ: BPMC), a leader in discovering and
developing targeted kinase medicines for patients with genomically
defined diseases, today announced its participation in the
following upcoming investor conferences:
- 38th Annual Canaccord Genuity Growth
Conference in Boston, MA on
Wednesday, August 8, 2018 at
3:00 p.m. E.T.
- 2018 Wedbush PacGrow Healthcare Conference in
New York, NY on Wednesday, August 15, 2018 at 9:10 am. E.T.
A live webcast of each presentation will be available by
visiting the Investors section of Blueprint
Medicines' website at http://ir.blueprintmedicines.com. A
replay of the webcast will be archived on Blueprint
Medicines' website for 30 days following each
presentation.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of
targeted and potent kinase medicines to improve the lives of
patients with genomically defined diseases. Its approach is rooted
in a deep understanding of the genetic blueprint of cancer and
other disease driven by the abnormal activation of kinases.
Blueprint Medicines is advancing multiple programs in clinical
development for subsets of patients with gastrointestinal stromal
tumors, hepatocellular carcinoma, systemic mastocytosis, non-small
cell lung cancer, medullary thyroid cancer and other advanced solid
tumors, as well as multiple programs in research and preclinical
development. For more information, please
visit www.blueprintmedicines.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-august-300690485.html
SOURCE Blueprint Medicines